Proteomics and biomarkers for ovarian cancer diagnosis

Annals of Clinical and Laboratory Science

Volumn 40, Issue 3, 2010, Pages 218-225

  Zhang, Bei ^a   Barekati, Zeinab ^a   Kohler, Corina ^a   Radpour, Ramin ^a   Asadollahi, Reza ^a   Holzgreve, Wolfgang ^b   Zhong, Xiao Yan ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

2 dimensional electrophoresis; Mass spectrometry; Microarrays; Ovarian cancer; Proteomics

Indexed keywords

AFAMIN; AMYLOID A PROTEIN; ANNEXIN 1; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; COLLAGEN ALPHA1 CHAIN; COOH TERMINAL OSTEOPONTIN; EMILIN2; FERRITIN LIGHT CHAIN; FIBRINOGEN ALPHA; FIBRINOGEN BETA; GLYCOSYLATED EOSINOPHIL DERIVED NEUROTOXIN; HAPTOGLOBIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 60; HEMOGLOBIN BETA CHAIN; N ACETYL GLUCOSAMINE KINASE; NUCLEOSIDE DIPHOSPHATE KINASE A; PA28 PROTEIN; PEBP1; PHOSPHOPROTEIN PHOSPHATASE 1; PREALBUMIN; PROHIBITIN; PROTEASOME ALPHA 6; PRX II; PRX III; TRANSFERRIN; TRUNCATED FORM TRANSTHYRETIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VON WILLEBRAND FACTOR;

BIOINFORMATICS; BLOOD; CANCER DIAGNOSIS; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL ELECTROPHORESIS; HUMAN; LASER CAPTURE MICRODISSECTION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN MICROARRAY; PROTEOMICS; REVIEW; SERUM; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

EARLY DIAGNOSIS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 77955822375     PISSN: 00917370     EISSN: 15508080     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Pury P, Lutz JM, Jundt G, Bouchardy C, Frick H, Ess S, Bordoni A, Konzelmann I, Levi F, Probst N. Switzerland statistics of cancer incidence (1986-2005). [Swiss Assn of Cancer Registries], December 2007, http://asrt.ch/asrt/newstat/in4ch8605.pdf.
3. Pury P, Lutz JM, Junker C, Gantenbein E. Switzerland statistics of cancer mortality (1986-2005). Swiss Assn of Cancer Registries, October 2007, http://asrt.ch/asrt/newstat/mo4ch8605.pdf.
4. Cvetkovic D. Early events in ovarian oncogenesis. Reprod Biol Endocrinol 2003;1:68.
5. Rapkiewicz AV, Espina V, Petricoin EF 3rd, Liotta LA. Biomarkers of ovarian tumours. Eur J Cancer 2004;40:2604-2612.
6. Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005;15(Suppl 3):274-281.
7. Munkarah A, Chatterjee M, Tainsky MA. Update on ovarian cancer screening. Curr Opin Obstet Gynecol 2007;19:22-26.
8. Hogdall E. Cancer antigen 125 and prognosis. Curr Opin Obstet Gynecol 2008;20:4-8.
9. Bast RC Jr. Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare. Trans Am Clin Climatol Assoc 2004;115:233-247.
10. Badgwell D, Bast RC Jr. Early detection of ovarian cancer. Dis Markers 2007;23:397-410.
11. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004;3:355-366.
12. Posadas EM, Davidson B, Kohn EC. Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature. Curr Opin Oncol 2004;16:478-484.
13. Tyers M, Mann M. From genomics to proteomics. Nature 2003;422:193-197.
14. Plebani M. Proteomics: the next revolution in laboratory medicine? Clin Chim Acta 2005;357:113-122.
15. de Hoog CL, Mann M. Proteomics. Annu Rev Genomics Hum Genet 2004;5:267-293.
16. Pandey A, Mann M. Proteomics to study genes and genomes. Nature 2000;405:837-846.
17. Kolch W, Mischak H, Pitt AR. The molecular make-up of a tumour: proteomics in cancer research. Clin Sci 2005;108:369-383.
18. Li XQ, Zhang SL, Cai Z, Zhou Y, Ye TM, Chiu JF. Proteomic identification of tumor-associated protein in ovarian serous cystadenocarinoma. Cancer Lett 2009;275:109-116.
19. Scholler N, Gross JA, Garvik B, Wells L, Liu Y, Loch CM, Ramirez AB, McIntosh MW, Lampe PD, Urban N. Use of cancer-specific yeast-secreted in vivo biotinylated recombinant antibodies for serum biomarker discovery. J Transl Med 2008;6:41.
20. An HJ, Kim DS, Park YK, Kim SK, Choi YP, Kang S, Ding B, Cho NH. Comparative proteomics of ovarian epithelial tumors. J Proteome Res 2006;5:1082-1090.
21. Ye B, Skates S, Mok SC, Horick NK, Rosenberg HF, Vitonis A, Edwards D, Sluss P, Han WK, Berkowitz RS, Cramer DW. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res 2006;12:432-441.
22. Ahmed N, Oliva KT, Barker G, Hoffmann P, Reeve S, Smith IA, Quinn MA, Rice GE. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer. Proteomics 2005;5:4625-4636.
23. Ahmed N, Barker G, Oliva KT, Hoffmann P, Riley C, Reeve S, Smith AI, Kemp BE, Quinn MA, Rice GE. Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer. Br J Cancer 2004;91:129-140.
24. Jackson D, Craven RA, Hutson RC, Graze I, Lueth P, Tonge RP, Hartley JL, Nickson JA, Rayner SJ, Johnston C, Dieplinger B, Hubalek M, Wilkinson N, Perren TJ, Kehoe S, Hall GD, Daxenbichler G, Dieplinger H, Selby PJ, Banks RE. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin Cancer Res 2007;13:7370-7379.
25. Hood BL, Malehorn DE, Conrads TP, Bigbee WL. Serum proteomics using mass spectrometry. Methods Mol Biol 2009;520:107-128.
26. Engwegen JY, Gast MC, Schellens JH, Beijnen JH. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci 2006;27:251-259.
27. Seibert V, Ebert MP, Buschmann T. Advances in clinical cancer proteomics: SELDI-TOF-mass spectrometry and biomarker discovery. Brief Funct Genomic Proteomic 2005;4:16-26.
28. Ardekani AM, Akhondi MM, Sadeghi MR. Application of genomic and proteomic technologies to early detection of cancer. Arch Iran Med 2008;11:427-434.
29. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004;3:367-378.
30. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-577. (Pubitemid 34178440)
31. Baggerly KA, Morris JS, Edmonson SR, Coombes KR. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst 2005;97:307-309.
32. Albrethsen J. Reproducibility in protein profiling by MALDI-TOF mass spectrometry. Clin Chem 2007;53:852-858.
33. Sheehan KM, Calvert VS, Kay EW, Lu Y, Fishman D, Espina V, Aquino J, Speer R, Araujo R, Mills GB, Liotta LA, Petricoin EF, 3rd, Wulfkuhle JD. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 2005;4:346-355.
34. Charboneau L, Tory H, Chen T, Winters M, Petricoin EF 3rd, Liotta LA, Paweletz CP. Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays. Brief Funct Genomic Proteomic 2002;1:305-315.
35. Wulfkuhle JD, Aquino JA, Calvert VS, Fishman DA, Coukos G, Liotta LA, Petricoin EF 3rd. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 2003;3:2085-2090.
36. Omenn GS. Strategies for plasma proteomic profiling of cancers. Proteomics 2006;6:5662-5673.
37. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006;24:971-983.
38. Chambers AF, Vanderhyden BC. Ovarian cancer biomarkers in urine. Clin Cancer Res 2006;12:323-327.
39. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845-867.
40. Diamandis EP. Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 2003;49:1272-1275.
41. Lin YW, Lin CY, Lai HC, Chiou JY, Chang CC, Yu MH, Chu TY. Plasma proteomic pattern as biomarkers for ovarian cancer. Int J Gynecol Cancer 2006;16(Suppl 1):139-146.
42. Zhu W, Wang X, Ma Y, Rao M, Glimm J, Kovach JS. Detection of cancer-specific markers amid massive mass spectral data. PNAS USA 2003;100:14666-14671.
43. Petricoin E 3rd, Liotta LA. The vision for a new diagnostic paradigm. Clin Chem 2003;49:1276-1278.
44. Petri AL, Simonsen AH, Yip TT, Hogdall E, Fung ET, Lundvall L, Hogdall C. Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology. Acta Obstet Gynecol Scand 2009;88:18-26.
45. Helleman J, van der Vlies D, Jansen MP, Luider TM, van der Burg ME, Stoter G, Berns EM. Serum proteomic patterns for ovarian cancer monitoring. Int J Gynecol Cancer 2008;18:985-995.
46. Lemaire R, Menguellet SA, Stauber J, Marchaudon V, Lucot JP, Collinet P, Farine MO, Vinatier D, Day R, Ducoroy P, Salzet M, Fournier I. Specific MALDI imaging and profiling for biomarker hunting and validation: fragment of the 11S proteasome activator complex, Reg alpha fragment, is a new potential ovary cancer biomarker. J Proteome Res 2007;6:4127-4134.
47. Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005;5:4589-4596.
48. Moshkovskii SA, Serebryakova MV, Kuteykin-Teplyakov KB, Tikhonova OV, Goufman EI, Zgoda VG, Taranets IN, Makarov OV, Archakov AI. Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. Proteomics 2005;5:3790-3797.
49. Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64:5882-5890.
50. Bergen HR 3rd, Vasmatzis G, Cliby WA, Johnson KL, Oberg AL, Muddiman DC. Discovery of ovarian cancer biomarkers in serum using NanoLC electrospray ionization TOF and FT-ICR mass spectrometry. Dis Markers 2003;19:239-249.
51. Ye B, Cramer DW, Skates SJ, Gygi SP, Pratomo V, Fu L, Horick NK, Licklider LJ, Schorge JO, Berkowitz RS, Mok SC. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 2003;9:2904-2911.
52. Yurkovetsky ZR, Linkov FY, D EM, Lokshin AE. Multiple biomarker panels for early detection of ovarian cancer. Future Oncol 2006;2:733-741.
53. Gagnon A, Ye B. Discovery and application of protein biomarkers for ovarian cancer. Curr Opin Obstet Gynecol 2008;20:9-13.
54. Liang SL, Chan DW. Enzymes and related proteins as cancer biomarkers: a proteomic approach. Clin Chim Acta 2007;381:93-97.
55. Lee CJ, Ariztia EV, Fishman DA. Conventional and proteomic technologies for the detection of early stage malignancies: markers for ovarian cancer. Crit Rev Clin Lab Sci 2007;44:87-114.